Orbimed Advisors Llc Sells 126,209 Shares of Passage Bio, Inc. (NASDAQ:PASG) Stock

Passage Bio, Inc. (NASDAQ:PASG) major shareholder Orbimed Advisors Llc sold 126,209 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $0.66, for a total transaction of $83,297.94. Following the completion of the transaction, the insider now owns 7,131,636 shares of the company’s stock, valued at approximately $4,706,879.76. This trade represents a 1.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, January 13th, Orbimed Advisors Llc sold 17,986 shares of Passage Bio stock. The stock was sold at an average price of $0.64, for a total transaction of $11,511.04.
• On Wednesday, January 8th, Orbimed Advisors Llc sold 75,007 shares of Passage Bio stock. The shares were sold at an average price of $0.68, for a total transaction of $51,004.76.
• On Monday, January 6th, Orbimed Advisors Llc sold 19,481 shares of Passage Bio stock. The stock was sold at an average price of $0.77, for a total transaction of $15,000.37.
• On Friday, December 20th, Orbimed Advisors Llc sold 230,321 shares of Passage Bio stock. The stock was sold at an average price of $0.60, for a total value of $138,192.60.
• On Wednesday, December 11th, Orbimed Advisors Llc sold 80 shares of Passage Bio stock. The stock was sold at an average price of $0.80, for a total value of $64.00.
• On Monday, December 9th, Orbimed Advisors Llc sold 54,181 shares of Passage Bio stock. The shares were sold at an average price of $0.84, for a total value of $45,512.04.
• On Friday, December 6th, Orbimed Advisors Llc sold 20,903 shares of Passage Bio stock. The stock was sold at an average price of $0.82, for a total value of $17,140.46.
• On Wednesday, December 4th, Orbimed Advisors Llc sold 76,200 shares of Passage Bio stock. The shares were sold at an average price of $0.79, for a total value of $60,198.00.

Passage Bio Stock Performance

Shares of PASG opened at $0.60 on Wednesday. The firm has a market cap of $36.87 million, a PE ratio of -0.51 and a beta of 1.54. Passage Bio, Inc. has a 52-week low of $0.45 and a 52-week high of $1.79. The business’s 50 day moving average price is $0.68 and its two-hundred day moving average price is $0.72.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP grew its holdings in Passage Bio by 0.8% in the third quarter. Vestal Point Capital LP now owns 6,100,000 shares of the company’s stock worth $4,270,000 after purchasing an additional 48,000 shares during the period. Lynx1 Capital Management LP boosted its position in shares of Passage Bio by 4.4% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,057,629 shares of the company’s stock worth $4,017,000 after purchasing an additional 211,758 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of Passage Bio during the 3rd quarter worth about $1,718,000. Geode Capital Management LLC grew its stake in shares of Passage Bio by 18.2% in the 3rd quarter. Geode Capital Management LLC now owns 509,516 shares of the company’s stock valued at $357,000 after buying an additional 78,406 shares during the period. Finally, Landscape Capital Management L.L.C. bought a new stake in Passage Bio in the 3rd quarter valued at about $38,000. Institutional investors and hedge funds own 53.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PASG shares. Canaccord Genuity Group restated a “buy” rating and issued a $13.00 price target on shares of Passage Bio in a research report on Thursday, November 14th. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Passage Bio in a report on Thursday, November 14th. Finally, Wedbush began coverage on shares of Passage Bio in a research report on Friday, November 29th. They set an “outperform” rating and a $4.00 price target on the stock.

About Passage Bio

Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.